Thromb Res

Risks of major arterial and venous thrombotic diseases after hospitalisation for influenza, pneumonia, and COVID-19: A population-wide cohort in 2.6 million people in Wales.

Keene S, Abbasizanjani H, Torabi F, ..., Whiteley WN, CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study

Thromb Res 245 (-) 109213 [2024-11-19; online 2024-11-19]

Tocilizumab reduces hypercoagulation in COVID-19 - Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial.

Almskog LM, Sjöström A, Sundén-Cullberg J, ..., Lampa J, Magnusson M

Thromb Res 243 (-) 109135 [2024-11-00; online 2024-08-30]

Category: Drug Discovery Category: Serology Type: Journal article

Associations between hemostatic markers and mortality in COVID-19 - Compounding effects of D-dimer, antithrombin and PAP complex.

Boknäs N, Laine C, Hillarp A, ..., Lindahl TL, Holmström M

Thromb Res 213 (-) 97-104 [2022-03-18; online 2022-03-18]

Category: Biochemistry Category: Health Type: Journal article

Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19

Stanne TM, Pedersen A, Gisslén M, Jern C

Thromb Res 204 (-) 13-15 [2021-08-00; online 2021-08-00]

Category: Biochemistry Category: Health Funder: Hjärt-Lungfonden Funder: KAW/SciLifeLab National COVID program Funder: VR Research Area: Biobanks for COVID-19 research Type: Journal article

Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.

Fletcher-Sandersjöö A, Bellander BM

Thromb Res 194 (-) 36-41 [2020-10-00; online 2020-06-18]

Type: Review